Solvay


07/11/19 -"We have made some adjustments to take into account the huge impairment and added some first costs (€120m for 2019-21) in the implementation of the €300-350m cost reduction plan to our P&L. "

Pages
52
Language
English
Published on
07/11/19
You may also be interested by these reports :
18/11/19
We understand k+s manoeuvres in an environment which can be impacted by many triggers, and we see the announcement of maintenance standstills cutting ...

13/11/19
Lanxess seems to have left the path of strong cyclicality and the respective impact on profitability. Nevertheless, the company could not completely ...

12/11/19
The discrepancy between H1 US-GAAP and IFRS accounts was not dramatic, but we continue to use European accounting standards as our universe is based ...

07/11/19
We have made some adjustments to take into account the huge impairment and added some first costs (€120m for 2019-21) in the implementation of the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO